How to Get Alprostadil (Caverject/MUSE) in New York

What Alprostadil Is and Why New York Patients Seek It

Alprostadil is synthetic prostaglandin E1 (PGE1). It relaxes smooth muscle in the corpus cavernosum, dilates cavernosal arteries, and produces erections sufficient for intercourse in men who have not responded to oral phosphodiesterase-5 (PDE5) inhibitors such as sildenafil or tadalafil. The FDA approved Caverject (intracavernosal alprostadil) in 1995 and MUSE (medicated urethral system for erection, 125, 1 to 000 mcg pellets) in 1996. Caverject FDA label.

The landmark randomized controlled trial by Linet and Ogrinc published in the New England Journal of Medicine enrolled 683 men with chronic erectile dysfunction. At the primary endpoint, 94.1% of intracavernosal alprostadil injections produced a response sufficient for intercourse, compared with 20.6% of placebo injections (P<0.001) [1]. That single data point explains why alprostadil remains the gold-standard second-line ED therapy when oral agents fail, and why New York urologists and telehealth clinicians prescribe it regularly.

New York City and the broader state represent one of the highest-volume prescription markets for ED pharmacotherapy in the United States, given the population density of roughly 19.6 million residents CDC population data. Demand for both brand-name Caverject and compounded alprostadil has grown alongside telehealth expansion since 2020.

Who Can Prescribe Alprostadil in New York

Any New York-licensed prescriber with authority to write Schedule-exempt prescriptions may prescribe alprostadil. Alprostadil is not a controlled substance, so DEA scheduling rules do not restrict who can prescribe it beyond standard professional-practice scope.

Specifically, the following practitioners may prescribe in New York:

Physicians (MD/DO). Full prescriptive authority under New York Education Law Article 131. Urologists, internists, and primary-care physicians routinely prescribe Caverject and MUSE after an appropriate clinical evaluation New York State Education Law §6521.

Nurse Practitioners (NP). New York granted NPs full independent practice authority effective January 2023. An NP with a Collaborative Practice Agreement was required before that date; today a certified NP may evaluate and prescribe alprostadil autonomously after completing the required independent-practice period [2].

Physician Assistants (PA). PAs in New York prescribe under a Collaboration Agreement with a supervising physician per Education Law Article 131-B. The agreement must include the clinical area (men's health or urology) to support alprostadil prescriptions.

No New York statute restricts alprostadil prescribing to urologists specifically. A well-documented telemedicine evaluation by any of the above prescriber types satisfies state requirements, provided the prescriber holds a New York license and the patient is physically located in New York at the time of the visit [3].

How Telehealth Alprostadil Prescribing Works in New York

New York permits telemedicine prescribing of alprostadil without a prior in-person visit, provided the provider establishes a valid patient-provider relationship during the synchronous video encounter. The New York State Department of Health codified this under 10 NYCRR Part 69-8 during the COVID-era expansions, and the provisions were made permanent for non-controlled substances.

A standard telehealth workflow at a New York-licensed platform includes:

1. Online intake form. You complete a detailed sexual-health history, medication list, and cardiovascular risk screen. Most platforms require a testosterone level, fasting lipid panel, HbA1c, PSA (if age 40+), and blood pressure reading within the past 12 months [4].
2. Video consultation (15 to 30 minutes). A licensed New York prescriber reviews your history, rules out contraindications (severe hypotension, sickle-cell disease, anatomical penile abnormalities incompatible with injection, concomitant vasoactive therapy), and selects the delivery form [5].
3. Prescription transmission. The prescriber sends a non-controlled electronic prescription to your chosen pharmacy. New York does not require a paper prescription for alprostadil.
4. Injection training. For Caverject, the FDA labeling requires that the first injection be administered in a clinical setting to determine the effective dose and to monitor for prolonged erection (priapism). Many telehealth platforms satisfy this by partnering with local New York urology offices for the initial in-office dose titration visit, or by conducting a supervised video-assisted self-injection session [6].

Telehealth visits for alprostadil in New York typically cost $75, $150 for the consultation. Ongoing refill visits may be asynchronous (messaging-based) once the initial prescription and titration are established.

The HealthRX clinical team uses a three-gate framework before approving telehealth alprostadil in New York patients: (1) confirmed PDE5-inhibitor failure or contraindication documented in the chart, (2) cardiovascular clearance with resting BP <160/100 mmHg confirmed within 90 days, and (3) patient demonstration of self-injection technique or willingness to attend an in-person first-dose session at a partnered New York urology clinic.

What Labs Are Needed Before Alprostadil in New York

Lab requirements are not unique to New York but reflect the American Urological Association (AUA) 2018 guideline on erectile dysfunction, which recommends a metabolic workup before initiating second-line ED therapy [7].

Minimum labs most New York prescribers request:

• Total and free testosterone. Hypogonadism affects roughly 38% of men with ED over 45. Low testosterone may need treatment before or alongside alprostadil [8].
• Fasting glucose and HbA1c. Diabetes is the single strongest independent predictor of ED; uncontrolled hyperglycemia (HbA1c >9%) may reduce alprostadil response and warrants optimization [9].
• Fasting lipid panel. Dyslipidemia contributes to penile arterial insufficiency. The AHA/ACC 2019 guideline defines cardiovascular risk targets that inform alprostadil candidacy [10].
• Complete blood count. Rules out sickle-cell disease or trait, an absolute contraindication to intracavernosal vasoactive agents per FDA labeling.
• PSA (age 40+). Required by most urology practices before initiating any men's health therapy to establish a baseline.

Blood pressure is checked at or before the consultation. Resting BP >160/100 mmHg on two readings should prompt antihypertensive optimization before alprostadil is started, given the additive hypotensive risk [11].

If all recent labs are on file (within 6 to 12 months), many New York telehealth platforms accept them via upload without requiring repeat draws.

Alprostadil Dosing: Caverject vs. MUSE

Caverject and MUSE use different delivery mechanisms and dose ranges. The right choice depends on patient preference, dexterity, anatomy, and the etiology of ED [12].

Caverject (intracavernosal injection, Pfizer): Starting dose for psychogenic or mixed ED is 2.5 mcg. Starting dose for neurogenic ED (post-radical prostatectomy, spinal cord injury) is 1.25 mcg. Dose is titrated upward in 2.5 to 5 mcg increments at the clinic until the patient achieves an erection lasting 60 minutes or less. Maximum recommended single dose is 40 mcg. The injection is given into the lateral aspect of the proximal third of the penis, avoiding visible veins. Onset is 5 to 20 minutes; duration is 30 to 60 minutes in most patients Caverject PI, FDA.

MUSE (intraurethral suppository, Meda Pharmaceuticals): Available in 125, 250, 500, and 1 to 000 mcg pellets. The patient inserts the applicator 3.2 cm into the urethra and deposits the pellet. Onset is 5 to 10 minutes; efficacy is lower than intracavernosal injection. In the key MUSE trial, 64.9% of at-home MUSE administrations produced erections sufficient for intercourse vs. 18.6% placebo (P<0.001) [13]. MUSE is preferred by patients who cannot or will not self-inject.

Compounded alprostadil: New York 503A pharmacies may compound alprostadil in custom concentrations (e.g., 20 mcg/mL or 40 mcg/mL) when commercially available products are unavailable, cost-prohibitive, or when combination formulas are clinically indicated. The New York State Board of Pharmacy oversees 503A compounders; they must comply with USP <797> sterile-compounding standards for injectables [14].

Pharmacy Options in New York for Alprostadil

Retail chain pharmacies. CVS, Rite Aid, Walgreens, and independent New York pharmacies stock brand Caverject and Edex (another branded alprostadil injection by Pfizer/Pharmacia). Stock levels vary by borough and region. Calling ahead is advisable because Caverject periodically experiences supply constraints.

Mail-order pharmacies. OptumRx, Express Scripts, and Costco Pharmacy ship to New York addresses. Standard shipping is 3, 5 business days; overnight shipping is available for an added fee. A valid New York prescription transmitted electronically by your prescriber is sufficient; no paper prescription is required [15].

503A compounding pharmacies. New York-licensed 503A compounders such as those accredited by the Pharmacy Compounding Accreditation Board (PCAB) may prepare patient-specific alprostadil formulations. A prescriber must send a valid prescription with the patient-specific formula. State law prohibits 503A pharmacies from shipping compounded sterile preparations to patients in other states without satisfying both state boards, but intrastate shipping within New York is permitted [16].

Cost without insurance. Caverject 20 mcg single-use vials cost approximately $85, $130 per vial at New York retail pharmacies. A GoodRx coupon may reduce this to $60, $90 per vial at select pharmacies. Compounded alprostadil 40 mcg/mL (multi-dose vial, 10 doses) typically runs $80, $120 from a New York 503A compounder, making it significantly more cost-efficient per dose [17].

New York Medicaid and Insurance Coverage for Alprostadil

New York Medicaid covers alprostadil for refractory erectile dysfunction, defined as ED that has not responded to or is contraindicated for oral PDE5 inhibitors. Coverage requires prior authorization (PA) from the Medicaid Managed Care plan or fee-for-service Medicaid [18].

Prior authorization documentation typically required:

1. Diagnosis code N52.x (erectile dysfunction, organic origin) or N52.01, N52.9 with specificity.
2. Documentation of trial and failure of at least one PDE5 inhibitor (drug name, dose, duration, and reason for failure or contraindication).
3. Labs confirming the metabolic evaluation described above.
4. Clinical notes from the evaluating prescriber confirming the indication.

New York's Medicaid Preferred Drug List (PDL) places alprostadil in a non-preferred tier requiring PA. Most commercially insured plans in New York (Empire BlueCross, Aetna, United Healthcare) apply similar PA requirements. The AUA's 2018 ED guideline statement supports medical necessity: "Intracavernosal injection therapy is recommended as a second-line treatment option for patients who desire a non-surgical option and have failed or are intolerant of oral PDE5 inhibitor therapy." [7]

Approval turnarounds for New York Medicaid PA range from 3 to 14 business days for standard review, or 72 hours for expedited review when the prescriber documents clinical urgency.

Transferring an Existing Alprostadil Prescription to New York

If you move to New York or are a temporary resident, transferring an existing alprostadil prescription from another state is straightforward because alprostadil is non-controlled.

New York law allows pharmacies to honor out-of-state prescriptions for non-controlled substances if the prescription meets New York requirements: prescriber name, DEA number (if required), patient name, drug, dose, quantity, and directions. For alprostadil, the DEA number is not required because it is not a scheduled drug [19].

Practically, the safest approach is to ask your out-of-state prescriber to transmit a new electronic prescription directly to your New York pharmacy. Most e-prescribing systems transmit across state lines without issue. Alternatively, a New York telehealth consultation can generate a fresh prescription from a New York-licensed provider within one to two business days, eliminating any uncertainty about out-of-state prescriber credentials.

Side Effects and Safety Monitoring in New York Patients

The most common adverse effect is penile pain at the injection site, reported in up to 37% of men in long-term extension data from the Linet NEJM trial [1]. Prolonged erection lasting more than four hours (priapism) occurs in roughly 1% of injections; this is a urological emergency requiring prompt treatment, typically with intracavernosal phenylephrine 200 to 500 mcg [20].

New York-based patients should identify a local emergency urology resource before starting injection therapy. NYC Health + Hospitals emergency departments and most Level I trauma centers in New York can manage priapism. Patients on alprostadil should keep the prescriber's after-hours number accessible.

Hematoma at the injection site occurs in approximately 3% of injections. Infection at the injection site is rare (<0.2%) with proper sterile technique [21].

Systemic hypotension is uncommon with intracavernosal dosing because systemic absorption is limited, but patients with baseline BP <90/60 mmHg or those on alpha-blockers (e.g., tamsulosin, doxazosin) require dose reduction and closer monitoring per FDA labeling [22].

MUSE carries a lower priapism risk but produces urethral burning in up to 32% of users in key trial data and hypotension-related dizziness in 3.3% of patients [13].

How Long Until You Receive Alprostadil in New York

The fastest path: a New York telehealth consultation today, prescription transmitted same day, overnight pharmacy delivery tomorrow. Total elapsed time: 24 to 48 hours from booking to dose in hand.

A more typical timeline:

• Day 0, 1: Complete telehealth intake, upload recent labs, schedule video visit.
• Day 1, 2: Video consultation, prescription issued.
• Day 2, 3: Pharmacy processes prescription; standard mail-order shipping begins.
• Day 3, 5: Medication arrives. First injection must be supervised (in-person or video-assisted depending on platform protocol).

If labs are not current and must be drawn at a New York LabCorp or Quest Diagnostics location, add 1, 3 business days for results. New York has over 400 patient service centers between the two major national lab networks, so same-day or next-day draws are rarely a logistical barrier [23].

Prior authorization, when required, adds 3, 14 business days. Patients seeking immediate access while PA is pending may pay out-of-pocket for the first supply and seek reimbursement once the PA is approved.